Fat possesses the desired softness for many reconstructive purposes including breast and facial malformations, repair of scars, and as filler for aesthetic purposes. Fat grafting is, however, hampered by unpredictability of results by formation of oil cysts, necrosis, and resorption of grafted tissue. Recent development of automated stem cell isolation techniques has made it feasible to enrich adipose tissue grafts with adipose-derived mesenchymal stem cells (MSCs), with or without stem cell expansion before grafting. Stem cells of mesenchymal origin possess inflammation-modulatory properties related to their expression of cytokines that may influence recipient tissue responses in grafting procedures. Moreover, they have been shown to improve vascularization through their ability to facilitate angiogenesis. Clinical application of stem cell enrichment requires, however, consistent and predictable results regarding long-term survival of both grafts and stem cells. Such data are currently scarce, although histological evaluation of fat grafts has been performed. We have here utilized reporter mice expressing luciferase and optical imaging to assess stem cell and fat graft survival, and also inflammation-modulatory effects of adipose tissue–derived mesenchymal stem cells (ATMSCs). We used fat from 2 transgenic reporter mice models, one in which all cells possess a genomic sequence coding for luciferase driven by 3 DNA binding sites for the inflammation regulatory transcription factor NF-κB and other where luciferase expression is driven with adipose-derived mesenchymal stem cells (MSCs), with or without stem cell expansion before grafting. Stem cells of mesenchymal origin possess inflammation-modulatory properties related to their expression of cytokines that may influence recipient tissue responses in grafting procedures. Moreover, they have been shown to improve vascularization through their ability to facilitate angiogenesis. Clinical application of stem cell enrichment requires, however, consistent and predictable results regarding long-term survival of both grafts and stem cells. Such data are currently scarce, although histological evaluation of fat grafts has been performed. We have here utilized reporter mice expressing luciferase and optical imaging to assess stem cell and fat graft survival, and also inflammation-modulatory effects of adipose tissue–derived mesenchymal stem cells (ATMSCs).
by a constitutively active promoter. The former mouse model has been shown to faithfully report NF-κB transcriptional activity in a number of tissues including adipose tissue.\textsuperscript{11}

**MATERIALS AND METHODS**

**Cells and Transgenic Mice**

Transgenic mice with luciferase driven by NF-κB have been described.\textsuperscript{15} ATMSCs were isolated from wild-type C57BL/6 mice or transgenic mice for luciferase in the same genetic background driven by a constitutive promoter (see Document, Supplemental Digital Content 1, which displays generation of transgenic mice, http://links.lww.com/PRSGO/A344). ATMSCs were isolated from visceral adipose tissue as described by Yu et al\textsuperscript{15} and differentiated, briefly described in Supplemental Digital Content 1. Skin fibroblasts were isolated by outgrowth from ear biopsies.

**Flow Cytometry**

ATMSCs were characterized by incubation with 10 \( \mu \)l primary antibody against Sca-1, CD105, CD106, CD44, CD29, CD73, CD11b, or CD45 (R&D Systems; Minneapolis, Minn.) for 30 minutes on ice. Cells were washed and incubated with phycoerythrin-labeled secondary Goat F(ab')2 Anti-rat IgG (R&D Systems; Minneapolis, Minn.). Cells were washed and analyzed by flow cytometry using rat IgG2A (R&D Systems; Minneapolis, Minn.) as isotype control. At least 10,000 events were counted for each sample.

**Grafts and Cell Enrichment**

Male mice transgenic for luciferase driven by the EF1α-based constitutive promoter or promoter with NF-κB-binding sites were used as donors of adipose tissue. Donor mice were killed by CO\(_2\) or cervical dislocation; abdomen was washed with 70\% ethanol and opened surgically. Visceral adipose tissue was dissected and washed extensively with phosphate-buffered saline (PBS) containing 1\% penicillin-streptomycin. The tissue was minced and washed by settling connective tissue at 1g, before the supernatant containing adipocyte aggregates was collected and washed once with PBS. Before tissue enrichment, all cells were expanded in vitro in DMEM:F12 with 10\% FCS, detached by trypsin treatment and centrifuged for 10 minutes at 300\,g. Cells were washed and then cultured in DMEM:F12 containing 1\% penicillin-streptomycin, 1\% antibiotic-antimycotic (St. Louis, Mo.) and resuspended at 1 \times 10\(^7\) cells per ml in PBS with 1\% penicillin-streptomycin.

**Grafting and Cell Injection**

A dorsal area on the side of the vertebral column of anesthetized recipient female mice was shaved and washed with 70\% ethanol. Each wild-type recipient animal received 166 \( \mu \)l adipose tissue without enrichment, or enriched with 2 \times 10\(^6\) mouse skin fibroblasts or ATMSCs, by a single subcutaneous injection 10 mm away from grafting area, deposited in a fan-shaped manner under the shaved area (approximately 1 cm\(^2\)) using a 0.9 mm fat injector (Tulip Medical Products; San Diego, Calif.) and secured with metal staples. Animals were housed and used in accordance with the Guide for Care and Use of Laboratory Animals and handled according to procedures approved by the National Ethics Committee for animal research (approval #FOTS 6476). No adverse phenotypes were observed.

**Histochemistry and Immunohistochemistry**

Grafts were dissected from animals and fixed in buffered 4\% formaldehyde for 24 to 48 hours. Tissues were embedded in paraffin and sectioned at 4-μm thicknesses in a microtome. Consecutive sections were used for hematoxylin and eosin (HE) (DAKO; Glostrup, Denmark) staining. HE-stained slides were assessed blindly by a histopathologist, and the most central cross section of the affected area was selected for immunohistochemistry (IHC). Sections were deparaffinized for CD31 IHC labeling as described in Supplemental Digital Content 1.

**Quantification of Adipocytes and Capillaries**

Images of IHC labeled tissue sections were acquired on a DMRE microscope fitted with a DFC 500 CCD camera (Application Suite [LAS] v4.1–4.4) to obtain 4080 × 3072 pixel color images (all from Leica Microsystems; Heidelberg, Germany). Overview images were acquired with an N Plan 2.5×/0.07 objective, and images to be used for quantitative analysis were acquired with a Plan Fluorotar 10×/0.3 objective. Image processing was adapted for analyses of both adipocyte cellular profiles and CD31 immunoreactive vascular structures in the same images (optimized and standardized contrast). For the computerized quantitative analyses, the open source software ImageJ (http://rsbweb.nih.gov/ij/) and Adobe Photoshop (CS5 or CC) were used. All tissue areas histologically separated from recipient tissues were analyzed, avoiding regions of necrosis or severe tissue repair. All samples’ analyses of adipocytes were performed using a specifically designed script: (1) total area, (2) number of adipocyte profiles, (3) area of each adipocyte, (4) total adipocyte area, and (5) adipocyte area relative to the total area were analyzed. In each image, CD31 immunoreactive tubular or circular (i.e., capillary vessel) structures were identified visually, uniquely labeled, and counted.

**In vivo Optical Imaging**

At the indicated time points after grafting, mice with luciferase positive (Luc\(^+\)) grafts or cells were anesthetized with isoflurane, the fur in the grafted area was removed, and 130 mg/kg luciferin (Biosynth; Staad, Switzerland) was injected intraperitoneally. After 10 minutes, the mice were placed in an IVIS Spectrum pCT instrument (Perkin Elmer; Waltham, Mass.), and photons were counted during 300-second exposures and analyzed with LivingImage v. 4.3.1 software.

**Statistical Analysis**

Benjamini–Hochberg correction was used for correction of multiple testing (R software), and the power of 2-sample comparison was calculated with Sampsiz software (http://sampsiz.sourceforge.net/).
RESULTS

To assess viability of fat grafts and cells, we generated a transgenic mouse strain that expresses Fire Fly luciferase in all tested tissues including fat (Fig. 1B) and subsequently isolated Luc⁺ ATMSCs from visceral fat and characterized the cells regarding bioluminescence (Fig. 1C), cell surface markers (Fig. 1D), and differentiation capacity (Fig. 1E). Isolated Luc⁺ ATMSCs were then injected subcutaneously on the back of isogenic wild-type animals. Bioluminescence from cells at the injection site was then measured at intervals for up to 15 weeks (Fig. 2) and found to decline rapidly during the first 2 weeks before reaching a stable
level at 10% to 20% of the initial luminescence at the end of the experiment, suggesting long-term survival of a reasonable fraction of the cells. To test the hypothesis that ATMSCs provide conditions favorable for adipose tissue survival in a cotransplantation setting, we grafted Luc+ fat subcutaneously on the back of wild-type animals without ATMSC enrichment (control) or enriched with wild-type ATMSCs before grafting. Bioluminescence was then measured from both groups of animals at intervals for several weeks (Fig. 3A). Bioluminescence from ATMSC-enriched and control Luc+ adipose tissue followed different trajectories; it was substantially higher in enriched adipose tissue already the first day after transplantation and increased during the first 6 days, notwithstanding variations between individuals (Fig. 3A). Bioluminescence from grafts without ATMSC enrichment was only marginally increased in the same period. This suggests that the presence of ATMSCs improved survival of the fat graft although it cannot be ruled out that improved access to the luciferase substrate through increased vascularization contributed to the increased luminescence. Either way, our results provide evidence for a supportive effect of ATMSCs on the adipose tissue graft survival for the first week. From day 6 and onwards, there was a steady decline in luminescence from enriched grafts until 48 days (Fig. 3A).

Three months after transplantation, the animals were killed, and the grafted material together with surrounding recipient tissue was subjected to histological assessment. Histologically, areas of cystic necrosis and repair tissue dominated all grafts (Fig. 3B, representative image from 1 animal). In specimens from 7 animals, 15% to 47% of central cross sections consisted of viable adipose tissue, and the highest ratios were seen in the enriched grafts, al-

---

**Fig. 2.** Survival of subcutaneously grafted Luc+ ATMSC. ATMSCs were isolated from HLuc transgenic mice and cultured for 3 passages before 5 × 10^5 cells were injected subcutaneously on the back of wild-type isogenic animals. At the indicated days after injection, luciferin was injected and animal imaged for counting of photons from the injected cells. Inset shows images of all animals at 2 selected time points. Bars indicate ±SD, n = 10.

---

**Fig. 3.** Survival of subcutaneous Luc+ fat grafts. A, The graph shows average total flux from fat grafts at the indicated time points after being grafted at day 0 with no or with ATMSC enrichment. The inset shows images of representative animals 6 days after transplantation. Dashed line, no enrichment; straight line, ATMCS enrichment. Bars indicate ±SD, n = 10. The statistical power of comparisons of the 2 groups at days 3, 6, and 14 was calculated to be 78%, 99%, and 94%, respectively. B, Upper panel shows HE-stained section of graft dissected from representative animal 101 days after transplantation. Middle and lower panels show higher magnification of selected areas indicated in the upper panel.
though no correlation between the ratios and enrichment protocol was observed (Table 1). The density of cytologically viable adipocytes in each individual graft varied between 97 and 336 per mm², the highest numbers observed in the stromal cell–enriched group (336 per mm²) and the skin fibroblast group (259 per mm²), but no statistically significant correlation to enrichment protocol was observed (Table 1). To explore the possibility that vascularization is more pronounced in ATMSC-enriched grafts, we analyzed immunohistochemically the grafts for the endothelial marker CD31. The density of CD31-positive capillaries varied considerably (10.1 to 57.6 per mm²), without any detectable trend toward improved vascularization in transplanted tissue enriched with ATMSCs (Table 1).

ATMSCs have been shown to modulate inflammatory processes in vitro and in vivo.7 We therefore tested whether ATMSCs affect inflammatory state of the fat grafts. To this end, we harvested adipose tissue from a transgenic mouse where adipocytes harbor a NF-κB–luciferase reporter construct. NF-κB–driven luminescence, with or without ATMSC enrichment, was then monitored regularly for 46 days. Initially, luminescence from the 3 groups of mice was found to vary substantially and inconsistently between time points after grafting (the first 3 wk, Fig. 4), suggesting variable degree of inflammation in the grafts, possibly because of mechanical tissue damage activating NF-κB signaling pathways. Contribution from cell proliferation is most likely low, as most cells in the graft are terminally differentiated adipocytes that have exited the cell cycle, and ATMSCs do not seem to proliferate after transplantation as judged from the drop in luminescence to a stable level seen in Figure 2. It cannot be ruled out, however, that integrated Luc+ immune cells cotransplanted with the adipose tissue enter the cell cycle on inflammatory cues and contribute to variation of luminescence. After the initial variations and approximately 30 days after transplantation, the grafts enriched with ATMSCs displayed increased luminescence as compared to those enriched with skin fibroblasts or without enrichment (Fig. 4, p value corrected for multiple testing), suggesting increased NF-κB activity in grafts enriched with ATMSCs.

ATMSC enrichment could possibly facilitate a more robust inflammatory response to an adequate stimulus as compared to nonenriched grafts. To test this possibility, mice grafted with or without ATMSC enrichment of the adipose tissue were challenged with lipopolysaccharide (LPS), a powerful inducer of NF-κB, by injection into a visceral fat pad at day 76 after grafting. Mice were imaged before and after LPS injection, and luminescence was quantified by photon counting (Fig. 5A). Grafts enriched with ATMSCs responded with a higher induction of luminescence than grafts without enrichment after the proinflammatory stimulus, suggesting that ATMSC enrichment contributed to a robust NF-κB response in the grafts.

It has been demonstrated that ATMSCs can detach from the surrounding tissue and migrate to sites of inflammation.14 Along this line, it is reasonable to suspect that ATMSCs in ectopically transplanted adipose tissue can also respond to a proinflammatory stimulus and migrate to other sites. To explore this, whole-body bioluminescence from LPS-injected animals was monitored for another 4 weeks. Figure 5B shows that luminescence appeared at the site of LPS injection 25 days after injection in 1 of 6 animals with ATMSC-enriched NF-κB–responsive fat graft. Guided by luminescence, the Luc+ structure was dissected and sectioned along the indicated line and evaluated histologically after HE staining (Fig. 5C). The interior lacks...
Fig. 5. Inflammatory response in subcutaneous NF-κB-Luc⁺ fat grafts. A, Seventy-six days after transplantation of NF-κB-Luc⁺ fat grafts subcutaneously on the back, with and without ATMSC enrichment, 3 mice were injected with 2 mg/kg LPS intraperitoneally and imaged 5 h after LPS injection; bars represent ±SD, P value from Student t test, n = 3. B, LPS-injected animals were imaged regularly for another 31 days after which 1 animal displayed luminescence from an abdominal structure near the site of previous LPS injection. The mouse was killed, and the luminescent structure was dissected and sectioned before HE staining. (C) left micrograph: 40x magnification of the whole section; right micrograph, 400x magnification of the neighboring section.
recognizable structures congruent with necrosis of adipose tissue, possibly because of extensive inflammation caused by the injected LPS. Histologically, the cyst rim contains adipocytes, fibroblasts in a collagenous matrix, chronic and acute inflammatory cells, and a tight network of capillaries visible in the upper corner (Fig. 5C, right micrograph). This is interpreted as a migration of populations of transplant-ed adipocytes that merge with surrounding native adipose tissue with no distinct front or border. These results suggest that inflammation and necrotic tissue have attracted NF-κB-Luc+ cells from the ectopic subcutaneous graft.

**DISCUSSION**

Here we show what, to our knowledge, is the first demonstration of the survival rate of ATMSC in real time after a clinically relevant grafting procedure. After an initial surge of graft-associated luminescence that may be associated with the grafting procedure itself or rapidly proliferating endothelial cells or macrophages, we demonstrate a long-term survival of a small fraction of transplanted Luc+ ATMSCs as judged by stable luminescence from the site of ATMSC transplantation. Luc+ fat grafts enriched with wild-type ATMSCs showed a trend toward higher luminescence than nonenriched fat for up to 7 weeks after grafting, suggesting that ATMSC enrichment has a beneficial effect on cotransplanted grafts. Also, ATMSC enrichment increased NF-κB activity in fat grafts in the same period as ATMSC improved survival. Additionally, when animals with NF-κB–Luc+ fat grafts were challenged with a proinflammatory stimulus, we found that ATMSC enrichment resulted in increased NF-κB response in the grafts. Of note, in 1 of 6 animals treated with a proinflammatory stimulus, NF-κB–Luc+ cells were found at an anatomical location different from the site of grafting, suggesting migration of fat-derived cells. Taken together, these results suggest that ATMSC enrichment improves the integrity of the grafts although only for a limited period. Notably, there was still detectable luminescence above background when the animals were killed for histological assessment, suggesting long-term survival of a fraction of the graft regardless of ATMSC enrichment. We cannot, however, distinguish between cell types in the grafts regarding survival because the grafts were produced by crude disruption of adipose tissue and likely contained various cell types, i.e., fibroblasts, mesenchymal stromal cells, endothelial cells, and leukocytes in addition to mature adipocytes, this requires further investigation. There are several possible reasons why the effect is time limited: (1) ATMSCs enter into apoptosis or necrosis due to insufficient nutrient supply or lack of appropriate cell contacts; (2) ATMSCs attain properties that no longer support adipocyte survival; (3) adipocytes no longer respond to survival factors from ATMSCs. Discrimination between these explanations requires further studies.

ATMSCs, graft-resident macrophages, and mature adipocytes may all be responsible for the observed NF-κB activation by LPS as they express Toll-like receptor 4 (the LPS receptor).15–17 The amplitude of the response indicates, however, that it comes from a large population of cells, suggesting that LPS induces NF-κB activation in the mature adipocytes. Alternatively, increased NF-κB activity could be caused by increased proinflammatory infiltration and thus be responsible for graft destruction at later time points. The increased response to a proinflammatory stimulus can be beneficial for tissue integration of the grafted material since an inflammatory response is considered necessary for regeneration of tissue in wound healing.18 Noteworthy is also the observation by Asterholm et al19 that expression of inflammatory factors in adipocytes is required for adequate adipose tissue remodeling in response to energy intake. Noteworthy is also the observation by Guneta et al20 who demonstrated marked differences between MSCs from breast fat and abdominal fat and it cannot be ruled out that ATMSCs-dependent graft survival depends on depot of origin.21

In a recent study, Kölle et al22 used enrichment of adipose tissue grafts in humans to demonstrate that stromal cell enrichment contributed to higher amounts of adipose tissue and newly formed connective tissue. Complementary to this, we detected considerable areas of tissue repair (mononuclear inflammatory cells, fibroblast-like cells, and capillaries) that in time would be expected to result in collagenous connective tissue. MSCs, including those found in adipose-derived stroma-vascular fraction, have been shown to facilitate angiogenesis.23 It can be speculated that stromal cells contributed to vascularization of the grafts in our experiments and thereby provided improved access to luciferin. However, when grafts were sectioned and analyzed histologically for tubular CD31-positive structures, i.e., capillaries, we could not detect any differences between sections from grafts with stromal cells, fibroblasts, or no enrichment. Although the number of animals was limited and the protocols were significantly different, our analyses confirm the observation by Kölle et al22 that stromal cell enrichment of grafts does not increase vessel density.

The identity of the migrated cells and mode of migration are unknown. However, we find it unlikely that cells located outside the site of grafting arrived at the site by being accidently injected into the blood stream. MSCs are large in size and have been shown to be trapped in the lung.24

We conclude that stromal cell enrichment may be used for reconstructive purposes to improve survival and modulate inflammatory responses in adipose tissue grafts although only for a limited period after grafting. However, the safety of the procedure needs further studies regarding migratory properties of MSCs to evaluate the risk of hyperplasia at unwanted anatomical locations.
ACKNOWLEDGMENT

The authors thank ImaGene-iT AB for valuable assistance in interpretation and quantitation of structures in histology images.

REFERENCES

1. Gir P, Brown SA, Oni G, et al. Fat grafting: evidence-based review on autologous fat harvesting, processing, reinjection, and storage. Plast Reconstr Surg. 2012;130:249–258.
2. Sterodimas A, de Faria J, Nicaretta B, et al. Tissue engineering with adipose-derived stem cells (ADSCs): current and future applications. J Plast Reconstr Aesthet Surg. 2010;63:1886–1892.
3. Yoshimura K, Sato K, Aoi N, et al. Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. Aesthetic Plast Surg. 2008;32:48–55; discussion 56.
4. Coleman SR. Structural fat grafts: the ideal filler? Clin Plast Surg. 2001;28:111–119.
5. Delay E, Garson S, Tousson G, et al. Fat injection to the breast: technique, results, and indications based on 880 procedures over 10 years. Aesthet Surg J. 2009;29:360–376.
6. Kakagia D, Pallua N. Autologous fat grafting: in search of the optimal technique. Surg Innov. 2014;21:327–336.
7. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20:14–20.
8. Lee SM, Lee SC, Kim SJ. Contribution of human adipose tissue-derived stem cells and the secretome to the skin allograft survival in mice. J Surg Res. 2014;188:280–289.
9. Murohara T. Autologous adipose tissue as a new source of progenitor cells for therapeutic angiogenesis. J Cardiovasc Pathol. 2009;15:155–163.
10. Mashiko T, Yoshimura K. How does fat survive and remodel after grafting? Clin Plast Surg. 2015;42:181–190.
11. Kielland A, Camassa LM, Døhlen G, et al. NF-κB activity in perinatal brain during infectious and hypoxic-ischemic insults revealed by a reporter mouse. Brain Pathol. 2012;22:499–510.
12. Carlsen H, Moskaug JØ, Fromm SH, et al. In vivo imaging of NF-κB activity, J Immunol. 2002;168:1441–1446.
13. Yu G, Wu X, Kilroy G, et al. Isolation of murine adipose-derived stem cells. Methods Mol Biol. 2011;702:29–56.
14. Sohrni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013;2013:130763.
15. Lindroos B, Saunonen R, Miettinen S. The potential of adipose stem cells in regenerative medicine. Stem Cell Rev. 2011;7:269–291.
16. Lin Y, Lee H, Berg AH, et al. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem. 2000;275:24255–24263.
17. Kopp A, Buechler C, Neumeier M, et al. Innate immunity and adipocyte function: ligand-specific activation of multiple Toll-like receptors modulates cytokine, adipokine, and chemokine secretion in adipocytes. Obesity (Silver Spring). 2009;17:648–656.
18. Maxson S, Lopez EA, Yoo D, et al. Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med. 2012;1:142–149.
19. Wernstedt Asterholm I, Tao C, Morley TS, et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014;20:103–118.
20. Guneta V, Tan NS, Sugii S, et al. Comparative study of adipose-derived stem cells from abdomen and breast. Ann Plast Surg. 2016;76:569–575.
21. Trojabøl Kølle SF, Oliveri RS, Gölovinski PV, et al. Importance of mesenchymal stem cells in autologous fat grafting: a systematic review of existing studies. J Plast Surg Hand Surg. 2012;46:59–68.
22. Kølle SF, Fischer-Nielsen A, Mathiassen AB, et al. Enrichment of autologous fat grafts with ex-vivo expanded adipose tissue-derived stem cells for graft survival: a randomised placebo-controlled trial. Lancet. 2013;382:1113–1120.
23. Kwon YW, Heo SC, Jeong GO, et al. Tumor necrosis factor-α-activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. Biochim Biophys Acta. 2013;1832:2136–2144.
24. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683–692.